BOSTON, MA, Rapport Therapeutics, leveraging receptor-associated proteins to advance precision neuromedicines, announced a $150 million Series B funding round.
Rapport Therapeutics, leveraging receptor-associated proteins to advance precision neuromedicines, announced a $150 million Series B funding round led by Cormorant Asset Management, with participation from Fidelity Management & Research Company, Goldman Sachs Asset Management, Logos Capital, Perceptive Advisors, Sofinnova Investments, Surveyor Capital, T. Rowe Price Associates, Third Rock Ventures, ARCH Venture Partners, and Johnson & Johnson Innovation.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
